Jessica J. Federer - 16 Mar 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Director
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Jessica J. Federer
Issuer symbol
SAGE
Transactions as of
16 Mar 2023
Net transactions value
$0
Form type
4
Filing time
17 Mar 2023, 16:09:44 UTC
Previous filing
17 Mar 2023
Next filing
16 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Options (Right to buy) Award $0 +19,894 $0.000000 19,894 16 Mar 2023 Common Stock 19,894 $43.64 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All of the shares subject to the option vest in equal monthly installments during the 36 months following March 16, 2023 (the "Grant Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Grant Date, subject to the reporting person's continued service as a director of the issuer through such date.